Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "adriamycin" wg kryterium: Wszystkie pola


Wyświetlanie 1-4 z 4
Tytuł:
Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects.
Autorzy:
Bartoszek, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/1043757.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
covalent binding to macromolecules
adriamycin
oxygen radicals
NADPH-cytochrome P450 reductase
Opis:
NADPH-cytochrome P450 reductase (P450 reductase) is one of the enzymes implicated in the metabolism of adriamycin, a very important clinically used antitumour drug. However, apart from the enzyme involvement, so far little was known about the chemical route and biochemical effects of this process. We demonstrated that the application of P450 reductase simultaneously with adriamycin to tumour cells in culture significantly increased cytotoxicity of the drug. Under tissue culture conditions, we noticed also that, in the presence of P450 reductase, adriamycin metabolite(s), displaying an altered spectrum within the visible light range were formed. This observation was taken adavantage of to study the metabolism of adriamycin in cell-free systems, using initially the enzyme isolated from rat liver and the recently obtained recombinant human P450 reductase. The reductive conversion of the drug turned out to be a multi-stage process, which occurred only under aerobic conditions and was accompanied by excessive NADPH consumption. Further research carried out with the aid of radical scavengers and radiolabelled adriamycin revealed that the enhancement of biological activity of adriamycin by P450 reductase stemmed from the formation of alkylating metabolite(s) rather than from the promotion of redox cycling known to be induced in the presence of anthracyclines.
Źródło:
Acta Biochimica Polonica; 2002, 49, 2; 323-331
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The influence of adriamycin on the CD4 and CD8 cells in the course of trichinellosis in mice
Autorzy:
Karmanska, K
Houszka, M.
Mista, D.
Stefaniak, E.
Powiązania:
https://bibliotekanauki.pl/articles/837229.pdf
Data publikacji:
1994
Wydawca:
Polskie Towarzystwo Parazytologiczne
Tematy:
parasite
mouse
mice
cell
trichinellosis
adriamycin
histopathology
Opis:
The effect of adriamycin on the behaviour of CD4⁺ and CD8⁺ cells in the course of trichinellosis in mice has been studied. The animals infected with 200 larvae per mouse were administered intraperitoneally adriamycin (Adriblastin from Farmitalia) at 1st and 28th day post infection (dpi), in a dosis of 0.2 mg. The mice were killed weakly for 6 weeks and then at the 60th dpi. The examinations were made on histologic sections from the spleen, mesenteric lymph node, jejunum and masseter muscle using immunofluorescent and immunoenzymatic methods with monoclonal antibody. The mice receiving adriamycin exhibited more CD8⁺ cells in the intestinal mucosa and by the end of the experiment also in the muscles in comparison with the control animals, which, however, did not affect the course of the infection.
Źródło:
Annals of Parasitology; 1994, 40, 4
0043-5163
Pojawia się w:
Annals of Parasitology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Adriamycin cardiomyopathy with congestive heart failure, cardiogenic shock and emergency heart transplant: 30-year follow up
Autorzy:
Mursleen, Asma
Harrison, Eric E.
Powiązania:
https://bibliotekanauki.pl/articles/1065074.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
doxorubicin cardiomyopathy
heart transplant survivor
heart transplantation
Opis:
Doxorubicin chemotherapeutic agent is widely utilized for many types of cancers since the late 1960s. Cardiomyopathy is a well-known side effect of doxorubicin often limiting its use. In many cases doxorubicin cardiomyopathy can lead to end stage cardiac failure requiring heart transplantation. The quality of life of heart transplant patients is exceptional with most patients being able to continue normal activities following recovery. There has been significant advancement in cardiac transplantation since it was first attempted in 1967 in Cape Town, South Africa. Drugs such as cyclosporine played an important role in preventing graft failure and prolonging patient survival. Cardiac transplant can extend a patients’ life by over a decade. The patient in this case, Mr. Glen Frank Spurling, has survived 30 years following his cardiac transplant surgery. In this article an overview of doxorubicin cardiotoxicity, cardiac transplantation, and an interview with Mr. Glen Frank Spurling is presented.
Źródło:
OncoReview; 2015, 5, 1; A5-A10
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-4 z 4

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies